| Name | Title | Contact Details |
|---|---|---|
Peter Wang |
Chief Technology Officer | Profile |
Meta Pharmaceutical Services is a Blue Bell, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PurposeCare is an integrated platform company that coordinates care in the community with a focus on individuals who are dually eligible for Medicaid and Medicare.
NantHealth is a transformational healthcare company converging biomolecular medicine and bioinformatics with technology services to empower physicians, patients, payers, pharma and researchers to transcend the traditional barriers of today’s healthcare system. NantHealth solutions are advancing diagnostics to better identify and target specific disease characteristics; transforming clinical and operational delivery with real time actionable clinical data, and promoting wellness for a healthier, happier world. We are building an integrated, evidence-based, omically-informed, personalized approach to the delivery of care and the development of next generation healthcare solutions. NantHealth is a subsidiary of NantWorks a company founded and led by Dr. Patrick Soon-Shiong. NantWorks is a convergence of next generation machine vision, object and voice recognition technologies, ultra-low power semiconductors, supercomputing, and advanced networks for the purpose of bringing the digital revolution to healthcare, commerce, and digital entertainment to an entirely new level. NantHealth envisions a world in which cutting-edge developments in science, technology, infrastructure and human ingenuity converge to advance one extraordinary mission: transforming healthcare for the benefit of every patient. We merge innovation with infrastructure; empowering more efficient and effective clinical decisions through advanced and actionable health information. By improving the accuracy and timeliness of data, we can deliver targeted healthcare intelligence for evolutionary personalized care. Our ultimate mission is to empower progress through uniquely informed decisions; to bring the impossible to life by harnessing the power of convergence for the well-being of humanity.
Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly`s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. We pride ourselves on creating a culture and work environment that is scientifically driven, ambitious, and collaborative. We encourage diversity of thought that leads to great innovation and are looking to add to our dynamic team great people who are driven to transform the lives of patients. We believe our Microbiome platform represents a best in class approach to developing biopharmaceutical agents from live biotherapeutic products. ABI-M201, our lead program in mildly to moderately active ulcerative colitis (UC), is currently in a phase 1b clinical trial. This program is part of a broader collaboration we established with Allergan in 2017 for gastrointestinal programs such as UC, Crohn`s disease and Irritable Bowel Syndromes with potential total development and commercial milestones of up to $2.8 billion. Our internal pipeline comprises first in class or best in class live microbial biotherapeutic approaches in areas such as oncology, immune mediated and metabolic disorders, and other areas of high medical need. Assembly is headquartered in Carmel, Indiana, while the R&D headquarters is in South San Francisco. The Company also has a microbiome manufacturing facility in Groton, CT, and offices in China.
NxStage is more than just a company; we are leading the renal revolution. By our own design, we`re at the leading edge of a movement to transform renal care. To make it simpler. To make it portable. To expand treatment options for clinicians by overcoming traditional barriers. To enhance patient freedom and fulfillment. With significant breakthroughs already behind us - and others in the pipeline - NxStage is finding itself at the forefront of dramatically improved renal care, thanks to innovative yet simple therapeutic solutions that benefit patients, caregivers, and society. Our approach – and success is inspiring patients and providers.